Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Now Covered by Analysts at Guggenheim

Guggenheim initiated coverage on shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) in a research note issued on Friday, MarketBeat Ratings reports. The firm set a “buy” rating and a $59.00 price target on the stock. Guggenheim‘s price objective suggests a potential upside of 148.95% from the company’s previous close.

DMRA has been the subject of a number of other research reports. HC Wainwright restated a “buy” rating and set a $45.00 target price on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, July 21st. Wall Street Zen lowered Damora Therapeutics, Inc. Common Stock from a “hold” rating to a “sell” rating in a research report on Saturday, October 31st. Wedbush reiterated an “outperform” rating and set a $40.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, September 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, September 14th. Finally, Jefferies Financial Group initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, July 27th. They set a “buy” rating and a $50.00 target price for the company. Three analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $46.38.

Damora Therapeutics, Inc. Common Stock Stock Up 8.4%

Shares of DMRA traded up $1.84 during trading hours on Friday, hitting $23.70. The company had a trading volume of 360,452 shares, compared to its average volume of 448,096. The stock’s 50 day moving average price is $22.72 and its 200 day moving average price is $25.70. Damora Therapeutics, Inc. Common Stock has a 52-week low of $4.95 and a 52-week high of $38.33. The firm has a market cap of $1.46 billion, a P/E ratio of -7.03 and a beta of 1.52.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.12. On average, research analysts expect that Damora Therapeutics, Inc. Common Stock will post -2.06 EPS for the current fiscal year.

Insider Activity at Damora Therapeutics, Inc. Common Stock

In other Damora Therapeutics, Inc. Common Stock news, CEO Jennifer Jarrett acquired 12,500 shares of the company’s stock in a transaction that occurred on Friday, September 25th. The stock was bought at an average price of $20.23 per share, for a total transaction of $252,875.00. Following the acquisition, the chief executive officer directly owned 512,500 shares in the company, valued at $10,367,875. The trade was a 2.50% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Squarepoint Ops LLC purchased a new stake in Damora Therapeutics, Inc. Common Stock in the second quarter worth about $303,000. Arizona State Retirement System acquired a new position in shares of Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at $260,000. Seven Fleet Capital Management LP acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the second quarter worth about $7,398,000. Finally, Braidwell LP purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at $42,146,000. Hedge funds and other institutional investors own 14.20% of the company’s stock.

More Damora Therapeutics, Inc. Common Stock News

Here are the key news stories impacting Damora Therapeutics, Inc. Common Stock this week:

• Positive Sentiment: Damora reported a third-quarter loss of $0.40 per share, narrower than analysts’ expected loss of $0.52, a favorable earnings surprise. Earnings results
• Neutral Sentiment: Guggenheim lowered its target to $59 from $60 but maintained its Buy rating, leaving a substantially bullish target despite the small reduction. MarketBeat coverage
• Negative Sentiment: HC Wainwright revised its 2026 and 2027 loss forecasts downward, including FY2026 EPS to ($1.73) from ($1.67) and FY2027 EPS to ($1.70) from ($1.59). It also expects somewhat larger losses in each of the listed quarters from Q4 2026 through Q4 2027. The firm kept its Buy rating and $45 target, but the worsening earnings outlook is a negative signal. MarketBeat coverage

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.